Welcome to our dedicated page for Dr Reddys Labs news (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr Reddys Labs stock.
Dr. Reddy's Laboratories (RDY) maintains its position as a global pharmaceutical innovator through strategic developments in generic medicines, biosimilars, and active pharmaceutical ingredients. This news hub provides investors and industry professionals with essential updates on corporate milestones, regulatory filings, and market expansions.
Access real-time information about earnings announcements, partnership agreements, and product pipeline advancements. Our curated collection features official press releases covering FDA approvals, manufacturing facility certifications, and therapeutic area breakthroughs in oncology and gastroenterology.
Monitor critical updates including patent litigation outcomes, emerging market entries, and sustainability initiatives. The repository serves as a reliable resource for understanding RDY's operational strategies and quality compliance across 75+ countries.
Bookmark this page for streamlined access to verified updates about Dr. Reddy's Laboratories. Check regularly for insights into biosimilar developments, API production innovations, and financial performance indicators shaping the global pharmaceutical landscape.
Dr. Reddy's Laboratories Ltd. has launched its authorized generic version of VASOSTRICT® (vasopressin injection, USP) in the U.S. This release, approved by the U.S. Food and Drug Administration, responds to a significant market demand, with the VASOSTRICT® brand generating approximately $878.5 million in U.S. sales over the past twelve months ending December 2021.
The product is supplied in a carton of 25 single-dose vials, each containing vasopressin 1 mL at 20 units/mL. This launch is particularly relevant during the ongoing COVID-19 pandemic.
Dr. Reddy's Laboratories has announced its definitive agreement to acquire Nimbus Health GmbH, a licensed pharmaceutical wholesaler based in Germany, focusing on medical cannabis. This acquisition involves an upfront payment and performance-based earn-outs expected over the next four years. With a growing medical cannabis market in Germany, currently valued at ~€122 million and experiencing significant growth, this strategic move aims to leverage Nimbus Health's strengths in serving patients with unmet medical needs. The transaction is subject to customary closing conditions.
Dr. Reddy’s Laboratories Ltd. has launched Venlafaxine ER Tablets, which are therapeutically equivalent to Osmotica Pharmaceutical's product. The FDA approved these tablets in strengths of 150 mg and 225 mg, contributing to the U.S. market with sales around $51 million for the year ending October 2021. The new products come in bottle sizes of 30 and 90. The release includes important safety information regarding suicidality risks associated with antidepressants, emphasizing careful monitoring for patients.
Dr. Reddy's Laboratories has launched Valsartan Tablets, a generic version of Diovan® approved by the U.S. FDA. The brand had U.S. sales of approximately $150 million for the twelve months ending October 2021 according to IQVIA Health. The Valsartan Tablets are available in various dosages, including 40 mg, 80 mg, 160 mg, and 320 mg. A warning regarding fetal toxicity is included, advising discontinuation if pregnancy is detected. This launch positions Dr. Reddy’s strategically within the generic pharmaceutical market.
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) has partnered with Prestige BioPharma Ltd. to exclusively supply and commercialize Prestige's trastuzumab biosimilar in select Latin American and Southeast Asian countries. This biosimilar, HD201, is intended for treating HER2 positive breast and metastatic gastric cancer. Prestige will manage production from South Korea, while Dr. Reddy’s handles marketing and local registrations. Both companies aim to enhance access to affordable oncology treatments in these emerging markets.
Prestige BioPharma and Dr. Reddy’s Laboratories have entered into an exclusive partnership for the commercialization of Prestige's trastuzumab biosimilar (HD201) in selected Latin American and Southeast Asian countries. This biosimilar is intended for treating HER2 positive breast cancer and metastatic gastric cancer. Prestige will supply the drug, while Dr. Reddy's will handle registrations and marketing. This collaboration aims to enhance access to affordable cancer treatment in emerging markets.
Dr. Reddy’s Laboratories has launched Ephedrine Sulfate Injection USP, a generic equivalent to Akovaz®, approved by the U.S. FDA. The U.S. market for this product generated approximately $67.5 million in sales over the last twelve months, ending August 2021. The injection is packaged in a 1 mL fill within a 2 mL single-dose vial, delivering 50 mg of ephedrine sulfate per mL. This launch aligns with Dr. Reddy’s commitment to providing affordable medications and addresses a significant market need.
Dr. Reddy’s Laboratories has received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules in 2.5 mg and 20 mg strengths, with tentative approvals for other strengths. This positions the company to gain 180 days of generic drug exclusivity for these products. The approval follows a settlement with Celgene (Bristol Myers Squibb) regarding REVLIMID® patents, which also allows Dr. Reddy’s to market generic versions starting from January 31, 2026. This development aims to provide a more affordable option for patients.
Dr. Reddy’s Laboratories Ltd. has launched Carmustine for Injection, USP, a therapeutic equivalent generic of BiCNU® approved by the U.S. Food and Drug Administration. The U.S. market for BiCNU® and its generics generated approximately $19.4 million in sales for the twelve months ending August 2021. Carmustine is provided as a lyophilized powder in a single-dose package. However, it carries warnings for myelosuppression and pulmonary toxicity, necessitating careful monitoring of patients' blood counts.
FAQ
What is the current stock price of Dr Reddys Labs (RDY)?
What is the market cap of Dr Reddys Labs (RDY)?
